Storia della carriera di Jason G. Fewell
Precedenti posizioni note di Jason G. Fewell
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMUNON, INC. | Corporate Officer/Principal | 01/06/2014 | 01/02/2021 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 01/01/2002 |
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Direttore Tecnico/Scientifico/R&S | 18/05/2010 | - |
Corporate Officer/Principal | 01/07/2003 | 18/05/2010 |
Formazione di Jason G. Fewell
Florida State University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
IMUNON, INC. | Health Technology |
Aziende private | 2 |
---|---|
Egen, Inc.
Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
- Borsa valori
- Insiders
- Jason G. Fewell
- Esperienza